Date published: 2026-8-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

BMAL1 CRISPR Activation Plasmid (h): sc-400808-ACT

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • BMAL1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
  • BMAL1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
  • The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by BMAL1 CRISPR Activation Plasmid (h) and BMAL1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the ARNTL transcriptional start site. One or both designs may be available
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BMAL1 Antibody (B-1): sc-365645
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    BMAL1 CRISPR Activation Plasmid (h)

    sc-400808-ACT
    20 µg
    $397.00

    BMAL1 CRISPR Activation Plasmid (h2)

    sc-400808-ACT-2
    20 µg
    $397.00

    ARNTL (BMAL1) is a core basic helix–loop–helix PAS transcription factor that heterodimerizes with CLOCK/NPAS2 to drive circadian gene expression programs via E-box elements. This complex regulates daily oscillations in metabolism, mitochondrial function, redox balance, DNA damage responses, and immune signaling, coordinating transcriptional feedback loops with PER and CRY repressors. In human biology, altered BMAL1 activity has been linked to circadian rhythm disruption with downstream impacts on metabolic homeostasis, inflammatory pathways, neurobehavioral phenotypes, and cellular stress resilience. BMAL1 also intersects with hypoxia and nuclear receptor networks, making it a useful node for studying temporal regulation of transcription and systems-level physiology in vitro.

    BMAL1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ARNTL expression without altering the underlying DNA sequence.

    BMAL1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ARNTL locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

    Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ARNTL transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous BMAL1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ARNTL locus and enabling the study of BMAL1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of BMAL1 pathway restoration in tumor cells with silenced or reduced ARNTL expression.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.